mutations presented the fact that, as explained down below, CLL therapy relies to the presence or absence of such mutations. The existing consensus is always that, apart from clonal mutations, subclonal mutations that has a variant allelic frequency ranging from 5 to 10% (and for that reason down below the brink of detection by common molecular app